ndww42 Sunday, 03/04/18 09:27:40 AM Re: None 0.010 Post # of 106694 $RXMD UPCOMING CATALYSTS / NEWS February NET revenues: Week of March 12th or 19th or sooner - should be record net revenues again with possibly our second 2M+ month. Acquisition details: With the latest announcement of the company's intent to purchase a pharmacy in Palm Beach County, we will see additional details around this purchase and what it means on the revenue side. Audited Annual Report: Report is due 3/31 and will be the second audited year. Having two years of audited fins is the gold standard for institutional monies to flow in. Conference call for shareholders: This occurs every quarter. Should happen around the release of the annual report. March Numbers: Week of April 12th or 19th - should be record revenues again with possibly our third 2M+ month. Additional technology partnerships / contracts: Progressive care is both a healthcare services and technology company. Expect additional PRs and contracts stating new revenues streams Institutional buying: We've had what looks to be institutional buying recently and I would venture to guess we will receive more news about institutions covering us and major investments after we have our two years of audited financials in April. Institutional stock coverage: Shital has made it clear that she'd like to have coverage of the stock by institutional analysts. We are seeing more and more signs of this and will hear more about it soon IMO. Online Pharmacy / e-Commerce: With the news of Bitcoin and Amazon looking to get into the pharmacy space, expect additional news on RXMD about becoming a major online pharmacy. CBD / MJ / HEMP: One of the latest major developments. Additional news about CBD and MJ will most likely be coming out in the next couple of months. They already stated they will have in-house compounding and R&D! This will boost sales big time as customers would like to see alternatives to addictive pain pills. Tech / Tele-Pharm news: With the latest development of this being a tech play, we should hear more about their plan for tele-Pharmco and also we should hear from our NASDAQ independent board member on the latest developments. Investor conferences to attract institutional investors: They will most likely PR these events over the coming months. New 340B contracts: Over the next month or two we will most likely hear about new 340B contracts from multiple partners New Long term care facility relationships: The company continues to be active in the community with doctors, patients and long term facilities. Expect additional partnerships on this front. Achieve accreditation for non-sterile compounding: One the company's stated goals for 2018 is receiving accreditation for non-sterile compounding. This will actually allow them to make more money with more of a backing. Traditional financing: Expect news of traditional financing over the coming year. Opening more Pharmco Pharmacy Resource Centers in retirement and long term care communities: Another 2018 goal of the company. They will announce more resource centers to again strengthen their relationships in the community. More out of state licenses: They've already obtained 14 state licenses where they can do business and planning to expand to more states. We may hear more about these revenue streams as they add to the bottom line. Purdue sales rep team: We should be hearing more about the Purdue pharma sales force to join the team for conducting out of state sales Expansion / M&A: We should be seeing additional PBM contracts related to their recent acquisition. I also believe we will hear more about additional acquisitions and other partnerships. NASDAQ uplisting: With traditional financing, 2 locations and a much higher PPS, I expect to start to hear more about the company's plan to uplist to NASDAQ. RXMD - King of the OTC Best of the Best!